Aptilon Announces the Shareholders' Approval of an Amendment to its Stock
Option Plan

MONTRÉAL, June 30 /CNW/ - Aptilon Corporation ("Aptilon" or the "Corporation") (TSX-V: APZ), an innovative leader of on-line marketing services to physicians, today announced that the amendment to the stock option plan (the "Plan") to fix the maximum number of Common Shares available for issuance under the Plan at 28,803,813 has been approved by a majority of its shareholders at the Corporation's annual meeting held on June 30, 2010.

    
    About Aptilon Corporation
    -------------------------
    

Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach and interact with physicians via the Internet through its innovative AxcelRx(SM) Live video detailing platform which hosts promotional, peer selling and other sales and marketing programs. Top ten US pharmaceutical companies have adopted Aptilon's AxcelRx(SM) solution to reach physicians. Aptilon provides the infrastructure necessary for pharmaceutical companies to build physician awareness, understanding, and product preference during all stages of a product's life cycle, from pre-launch education through end stage support. For more information, visit www.aptilon.com.

AxcelRx(SM) and ReachNet(SM) are service marks of Aptilon Corporation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

%SEDAR: 00022191EF

For further information: Denis Martineau, President, Aptilon Corporation, 1-888-544-8866, [email protected]